Cargando…
Review of the pharmacology and clinical studies of micafungin
Micafungin, like other members of the echinocandin class, has a unique mechanism of action that inhibits the synthesis of 1,3-β-D glucans in the fungal cell wall. It has been approved for treatment of esophageal candidiasis, invasive candidiasis including candidemia, and for prophylaxis of Candida i...
Autores principales: | Bormann, Alison M, Morrison, Vicki A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802128/ https://www.ncbi.nlm.nih.gov/pubmed/20054447 |
Ejemplares similares
-
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011) -
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017) -
Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin
por: Shirazi, Fazal, et al.
Publicado: (2015) -
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
por: Wiederhold, Nathan P, et al.
Publicado: (2009) -
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)